All News

The FDA has approved Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on the results from the Phase 3 TITAN study.

A recent clinical study demonstrated positive long-term benefits of the early intervention combination treatment of metformin plus vildagliptin (Galvus, Norvartis), a dipeptidyl peptidase-4 [DPP-4] inhibitor, for type 2 diabetes (T2D).

Top news of the day from across the health care landscape.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

Researchers have found that methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may offer an effective solution to relieving patients' opioid-induced constipation with minimal adverse effects.

The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.

Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.

Research demonstrates a new direction in cell signaling and treatment for chronic inflammatory diseases such as psoriasis, asthma, and HIV.

The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care.

The parties included in this agreement in principle represent some of the more than 2,600 lawsuits filed against Purdue Pharma concerning opioids, including the company’s OxyContin products.

What is causing the loss of blood pressure control?

The significant jump in hospital-owned specialty pharmacies bolsters the belief that health system leaders increasingly understand how these services enable their organizations to enhance patient care and achieve market differentiation.

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.

Pharmacy Universe podcast host Deeb Eid, PharmD talks with Tim Ulbrich, PharmD, Associate Dean of Student Success and Professor of Pharmacy Practice at Northeast Ohio Medical University College of Pharmacy.

An over-the-counter and prescription drug, ranitidine is an H2 (histamine-2) blocker that decreases the amount of acid created by the stomach.

Tenapanor, a novel treatment, is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3.

Nabeel Qureshi, PharmD, expands our understanding of the typical Medical Science Liaison role by taking a look at his position in managed markets in an interview with Matt Paterini of The Nontraditional Pharmacist podcast.

Top news of the week from Specialty Pharmacy Times.

Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.

As an increasing number of youth are using e-cigarette products, the FDA has announced a federal plan intended to clear the market of unauthorized, nontobacco-flavored e-cigarette products.

Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.

The glucagon injection is designed to reduce the steps and time needed to prepare and administer medicine for severe hypoglycemia.

New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.

London Mayor Sadiq Khan has called for broader availability of pre-exposure prophylaxis drugs in his welcoming speech at the Fast-Track Cities 2019 conference, where leaders from 300 cities around the world will discuss municipal responses to HIV, tuberculosis, and viral hepatitis.

The #ThankAPharmacist campaign has celebrated and honored pharmacists for the last 5 years.

Suicide is the second leading cause of death among 15-29-year-olds, and one person dies every 40 seconds because of it. This tragedy is preventable with the right education and awareness.

After the Oklahoma case ruling, Johnson & Johnson stocks rallied, but the ruling is a warning to industry leaders that change is necessary.

A recent phase 2 clinical trial found MicuRx Pharmaceuticals’ contezolid acefosamil (MRX-4) to be effective in treating acute bacterial skin and skin structure infections (ABSSSI) with dosing regimens that appeared to be safe and well-tolerated.